<DOC>
	<DOCNO>NCT00237211</DOCNO>
	<brief_summary>To investigate safety efficacy letrozole monotherapy dose 2.5 mg/day postmenopausal patient breast cancer , determine blood concentration letrozole hormone .</brief_summary>
	<brief_title>Study High-dose Letrozole Therapy Postmenopausal Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Patients histologically document breast cancer . Patients hormone receptor ( ER and/or PgR ) status positive unknown Patients amenorrheic precede 12 month . Patients 20 year old young 75 year . Patients history postoperative adjuvant therapy history endocrine therapy tamoxifen treatment progression recurrence lesion . The endocrine therapy , however , exceed one regimen . Patients progress lesion . Patients sufficient organ function evaluate safety Patients whose performance status ( PS ) classify 0ï½ž2 . Patients residual effect previous treatment Patients concurrent previous malignant disease ( exclude uterine carcinoma insitu ) . Patients hypercalcemia uncontrollable cardiac disease ( include history serious cardiac disease ) Patients previously receive aromatase inhibitor . Patients lymphangitistype lung metastasis symptomatic brain metastasis . Other protocoldefined inclusion / exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>letrozole</keyword>
	<keyword>breast cancer</keyword>
</DOC>